Latest news
Teva provides guidance for UZEDY in 2024 and an update of mdc-TJK
MedinCell is a clinical- and commercial-stage biopharmaceutical company. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier-one pharmaceutical companies and foundations to improve Global Health through new therapeutic options.
Latest news
Teva provides guidance for UZEDY in 2024 and an update of mdc-TJK
Session en français
Mardi 19 décembre, 18h30 : Présentation des résultats du premier semestre de l'année fiscale 2023-24
English session
Tuesday, December 19, 6:30 pm: Half-year earnings call (April 1st - September 30th)
CONTACT